ReviewFrontiers in microbiology2017
Antifungal Therapy for Systemic Mycosis and the Nanobiotechnology Era: Improving Efficacy, Biodistribution and Toxicity.
Review in Frontiers in microbiology, 2017. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 31 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
31 citing papers in PubMed, 90 citations in OpenAlex.
- Development of Oral pH-Sensitive Eudragit L100-FunctionalizedACS omega · 2026Article
- Nanoformulations of essential oils for the treatment of fungal diseases, with a focus on dermatophytes.Archives of microbiology · 2026Review
- Development and Optimization of Multi-Well Colorimetric Assays for Growth ofJournal of fungi (Basel, Switzerland) · 2025Article
- Chitosan nanoparticles encapsulating farnesol show potent antifungal activity against Candida albicans biofilms.Brazilian journal of microbiology : [publication of the Brazilian Society for Microbiology] · 2025Article
- Review
- Review
- Nanotechnology-based Drug Delivery of Topical Antifungal Agents.Pharmaceutical nanotechnology · 2024Review
- Molecular characterization of fungal endophthalmitis and keratitis caused by yeasts.Medical mycology · 2022Article
- A Current Overview of Cyclodextrin-Based Nanocarriers for Enhanced Antifungal Delivery.Pharmaceuticals (Basel, Switzerland) · 2022Review
- The Effects of Intravitreal Administration of Antifungal Drugs on the Structure and Mechanical Properties Peripheral Blood Erythrocyte Surface in Rabbits.International journal of molecular sciences · 2022Article
- An insight into SARS-CoV-2 structure, pathogenesis, target hunting for drug development and vaccine initiatives.RSC medicinal chemistry · 2022Review
- Ceragenin-Coated Non-Spherical Gold Nanoparticles as Novel Candidacidal Agents.Pharmaceutics · 2021Article
- The Search for Putative Hits in Combating Leishmaniasis: The Contributions of Natural Products Over the Last Decade.Natural products and bioprospecting · 2021Review
- HPLC Method Validated for Quantification of Fluconazole Co-Encapsulated with Propolis Within Chitosan Nanoparticles.Indian journal of microbiology · 2021Article
- Characterisation, pathogenicity and hydrolytic enzyme profiling of selected Fusarium species and their inhibition by novel coumarins.Archives of microbiology · 2021Article
- Antifungal Nano-Therapy in Veterinary Medicine: Current Status and Future Prospects.Journal of fungi (Basel, Switzerland) · 2021Review
- Reassessing the Use of Undecanoic Acid as a Therapeutic Strategy for Treating Fungal Infections.Mycopathologia · 2021Review
- One Century of Study: What We Learned aboutJournal of fungi (Basel, Switzerland) · 2021Review
- Current applications and prospects of nanoparticles for antifungal drug delivery.EXCLI journal · 2021Review
- Poly-ε-caprolactone Nanoparticles Loaded with 4-Nerolidylcatechol (4-NC) for Growth Inhibition ofAntibiotics (Basel, Switzerland) · 2020Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors at 2 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Fungal diseases have been emerging as an important public health problem worldwide with the increase in host predisposition factors due to immunological dysregulations, immunosuppressive and/or anticancer therapy. Antifungal therapy for systemic mycosis is limited, most of times expensive and causes important toxic effects. Nanotechnology has become an interesting strategy to improve efficacy of traditional antifungal drugs, which allows lower toxicity, better biodistribution, and drug targeting, with promising results
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.